克唑替尼在一名间充质-上皮转化过表达/荧光原位杂交阴性/二代测序阴性的晚期肺腺癌患者中的疗效：病例报告
Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report.
作者信息
Song Peng, Liu Li, Liu Yutao, Zhang Tao, Guo Lei, Li Weihua, Ying Jianming, Yang Lin, Gao Shugeng
机构信息
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Transl Cancer Res. 2019 Apr;8(2):705-708. doi: 10.21037/tcr.2019.03.14.
Crizotinib, an oral ATP-competitive tyrosine kinase inhibitor (TKI), has shown significant activity against advanced non-small cell lung cancer (NSCLC) tumors harboring mesenchymal-epithelial transition (MET) amplification or exon 14 mutation. Methods to detect MET alteration includes immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) and reverse transcription polymerase chain reaction (RT-PCR). Despite multiple methods for detecting MET alteration, the response to crizotinib in advanced NSCLC patients according to the results of MET IHC staining is still unknown. This case showed effectiveness of crizotinib in a pretreated patient with advanced lung adenocarcinoma detected as MET overexpression/FISH-negative/NGS-negative. MET overexpression might be a biomarker for predicting efficacy of crizotinib.
克唑替尼是一种口服的ATP竞争性酪氨酸激酶抑制剂（TKI），已显示出对携带间充质-上皮转化（MET）扩增或外显子14突变的晚期非小细胞肺癌（NSCLC）肿瘤具有显著活性。检测MET改变的方法包括免疫组织化学（IHC）、荧光原位杂交（FISH）、下一代测序（NGS）和逆转录聚合酶链反应（RT-PCR）。尽管有多种检测MET改变的方法，但根据MET免疫组化染色结果，晚期NSCLC患者对克唑替尼的反应仍不清楚。本病例显示，克唑替尼对一名经预处理的晚期肺腺癌患者有效，该患者检测为MET过表达/FISH阴性/NGS阴性。MET过表达可能是预测克唑替尼疗效的生物标志物。
Zotero 插件